Pharmacological interventions for preventing acute mountain sickness: a network meta-analysis and trial sequential analysis of randomized clinical trials

References

• Hackett PH, Roach RC. High-altitude illness. N Engl J Med. 2001;345:107–114.
   PubMed Web of Science ®Google Scholar
• Mairer K, Wille M, Burtscher M. The prevalence of and risk factors for acute mountain sickness in the Eastern and Western Alps. High Alt Med Biol. 2010;11:343–348.
   PubMed Web of Science ®Google Scholar
• Murdoch D. Altitude sickness. BMJ Clin Evid. 2010;2010:1209.
   PubMedGoogle Scholar
• Basnyat B, Murdoch DR. High-altitude illness. Lancet. 2003;361:1967–1974.
   PubMed Web of Science ®Google Scholar
• Bärtsch P, Swenson ER. Clinical practice: acute high-altitude illnesses. N Engl J Med. 2013;368:2294–2302.
   PubMed Web of Science ®Google Scholar
• Fiore DC, Hall S, Shoja P. Altitude illness: risk factors, prevention, presentation, and treatment. Am Fam Phys. 2010;82:1103–1110.
   PubMed Web of Science ®Google Scholar
• Ritchie ND, Baggott AV, Andrew Todd WT. Acetazolamide for the prevention of acute mountain sickness—a systematic review and meta-analysis. J Travel Med. 2012;19:298–307.
   PubMed Web of Science ®Google Scholar
• Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777–784.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. 5.1.0 edition; [cited 2017 Jul 14]. Available from: http://handbook-5-1.cochrane.org/
   Google Scholar
• Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–1558.
   PubMed Web of Science ®Google Scholar
• Van Rhee HJ, Suurmond R, Hak T. User manual for meta-essentials: workbooks for meta-analysis (Version 1.0). Rotterdam, The Netherlands: Erasmus Research Institute of Management; [cited 2017 Jul 14]. Available from: www.erim.eur.nl/research-support/meta-essentials
   Google Scholar
• Thorlund K, Engstrom J, Wetterslev J, et al. Trial sequential analysis. Copenhagen trial unit; [cited 2017 Jul 14]. Available from: http://www.ctu.dk/tools-and-links/trial-sequential-analysis.aspx
   Google Scholar
• Epigear MetaXL; [cited 2017 Jul 14]. Available from: http://www.epigear.com/index_files/contact.html
   Google Scholar
• Basnyat B, Gertsch JH, Johnson EW, et al. Efficacy of low-dose acetazolamide (125 mg BID) for the prophylaxis of acute mountain sickness: a prospective, double-blind, randomized, placebo-controlled trial. High Alt Med Biol. 2003;4:45–52.
   PubMed Web of Science ®Google Scholar
• Basnyat B, Gertsch JH, Holck PS, et al. Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial. High Alt Med Biol. 2006;7:17–27.
   PubMed Web of Science ®Google Scholar
• Basnyat B, Holck PS, Pun M, et al. Spironolactone does not prevent acute mountain sickness: a prospective, double-blind, randomized, placebo-controlled trial by SPACE Trial Group (spironolactone and acetazolamide trial in the prevention of acute mountain sickness group). Wilderness Environ Med. 2011;22:15–22.
   PubMed Web of Science ®Google Scholar
• Bradwell AR, Myers SD, Beazley M, et al. Exercise limitation of acetazolamide at altitude (3459 m). Wilderness Environ Med. 2014;25:272–277.
   PubMed Web of Science ®Google Scholar
• Carlsten C, Swenson ER, Ruoss S. A dose-response study of acetazolamide for acute mountain sickness prophylaxis in vacationing tourists at 12,000 feet (3630 m). High Alt Med Biol. 2004;5:33–39.
   PubMed Web of Science ®Google Scholar
• Chen GZ, Zheng CR, Qin J, et al. Inhaled budesonide prevents acute mountain sickness in young Chinese men. J Emerg Med. 2015;48:197–206.
   PubMed Web of Science ®Google Scholar
• Choi PC, Lee JH. Comparison of methazolamide and acetazolamide for prevention of acute mountain sickness in adolescents. J Emerg Med Public Health. 2011;22:523–530.
   Google Scholar
• Chow T, Browne V, Heileson HL, et al. Ginkgo biloba and acetazolamide prophylaxis for acute mountain sickness: a randomized, placebo-controlled trial. Arch Intern Med. 2005;165:296–301.
   PubMedGoogle Scholar
• Gertsch JH, Basnyat B, Johnson EW, et al. Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT). BMJ. 2004;328:797.
   PubMed Web of Science ®Google Scholar
• Gertsch JH, Lipman GS, Holck PS, et al. Prospective, double-blind, randomized, placebo-controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache: the Headache Evaluation at Altitude Trial (HEAT). Wilderness Environ Med. 2010;21:236–243.
   PubMed Web of Science ®Google Scholar
• Gertsch JH, Corbett B, Holck PS, et al. Altitude Sickness in Climbers and Efficacy of NSAIDs Trial (ASCENT): randomized, controlled trial of ibuprofen versus placebo for prevention of altitude illness. Wilderness Environ Med. 2012;23:307–315.
   PubMed Web of Science ®Google Scholar
• Hillenbrand P, Pahari AK, Soon Y, et al. Prevention of acute mountain sickness by acetazolamide in Nepali porters: a double-blind controlled trial. Wilderness Environ Med. 2006;17:87–93.
   PubMed Web of Science ®Google Scholar
• Kanaan NC, Peterson AL, Pun M, et al. Prophylactic acetaminophen or ibuprofen result in equivalent acute mountain sickness incidence at high altitude: a prospective randomized trial. Wilderness Environ Med. 2017;28:72–78.
   PubMed Web of Science ®Google Scholar
• Kayser B, Hulsebosch R, Bosch F. Low-dose acetylsalicylic acid analog and acetazolamide for prevention of acute mountain sickness. High Alt Med Biol. 2008;9:15–23.
   PubMed Web of Science ®Google Scholar
• Ke T, Wang J, Swenson ER, et al. Effect of acetazolamide and gingko biloba on the human pulmonary vascular response to an acute altitude ascent. High Alt Med Biol. 2013;14:162–167.
   PubMed Web of Science ®Google Scholar
• Lipman GS, Kanaan NC, Holck PS, et al. Ibuprofen prevents altitude illness: a randomized controlled trial for prevention of altitude illness with nonsteroidal anti-inflammatories. Ann Emerg Med. 2012;59:484–490.
   PubMed Web of Science ®Google Scholar
• Lipman GS, Pomeranz D, Burns P, et al. A randomized controlled trial of budesonide versus acetazolamide for the prevention of acute mountain sickness. Am J Med. 2017;13. DOI:10.1016/j.amjmed.2017.05.034
   Web of Science ®Google Scholar
• Moraga FA, Flores A, Serra J, et al. Ginkgo biloba decreases acute mountain sickness in people ascending to high altitude at Ollagüe (3696 m) in northern Chile. Wilderness Environ Med. 2007;18:251–257. Erratum in: Wilderness Environ Med. 2008;19:51.
   PubMed Web of Science ®Google Scholar
• Parati G, Revera M, Giuliano A, et al. Effects of acetazolamide on central blood pressure, peripheral blood pressure, and arterial distensibility at acute high altitude exposure. Eur Heart J. 2013;34:759–766.
   PubMed Web of Science ®Google Scholar
• Sikri G, Srinivasa AB, Grewal RS. Is concurrent prophylactic use of acetazolamide and dexamethasone superior to acetazolamide alone in un-acclimatized lowlanders on ascent to high altitude? Indian J Physiol Pharmacol. 2014;58:87–91.
   PubMedGoogle Scholar
• van Patot MC, Leadbetter G, 3rd, Keyes LE, et al. Prophylactic low-dose acetazolamide reduces the incidence and severity of acute mountain sickness. High Alt Med Biol. 2008;9:289–293.
   PubMed Web of Science ®Google Scholar
• Wang J, Ke T, Zhang X, et al. Effects of acetazolamide on cognitive performance during high-altitude exposure. Neurotoxicol Teratol. 2013;35:28–33.
   PubMed Web of Science ®Google Scholar
• Wright AD, Beazley MF, Bradwell AR, et al. Medroxyprogesterone at high altitude. The effects on blood gases, cerebral regional oxygenation, and acute mountain sickness. Wilderness Environ Med. 2004;15:25–31.
   PubMed Web of Science ®Google Scholar
• Zheng CR, Chen GZ, Yu J, et al. Inhaled budesonide and oral dexamethasone prevent acute mountain sickness. Am J Med. 2014;127:1001–1009.e2.
   PubMed Web of Science ®Google Scholar
• Imray C, Booth A, Wright A, et al. Acute altitude illnesses. BMJ. 2011;343:d4943.
   PubMed Web of Science ®Google Scholar
• Swenson ER. Carbonic anhydrase inhibitors and high altitude illnesses. Subcell Biochem. 2014;75:361–386.
   PubMedGoogle Scholar
• Luks AM, McIntosh SE, Grissom CK, et al. Wilderness Medical Society. Wilderness Medical Society practice guidelines for the prevention and treatment of acute altitude illness: 2014 update. Wilderness Environ Med. 2014;25:S4–S14.
   PubMed Web of Science ®Google Scholar
• Low EV, Avery AJ, Gupta V, et al. Identifying the lowest effective dose of acetazolamide for the prophylaxis of acute mountain sickness: systematic review and meta-analysis. BMJ. 2012;345:e6779.
   PubMed Web of Science ®Google Scholar
• Xiong J, Lu H, Wang R, et al. Efficacy of ibuprofen on prevention of high altitude headache: a systematic review and meta-analysis. PLoS One. 2017;12:e0179788.
   PubMed Web of Science ®Google Scholar
• Pandit A, Karmacharya P, Pathak R, et al. Efficacy of NSAIDs for the prevention of acute mountain sickness: a systematic review and meta-analysis. J Commun Hosp Intern Med Perspect. 2014;4. doi: 10.3402/jchimp.v4.24927
   Google Scholar